Ratings Novogene Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
11.88 ^CNY	+1.19%		-10.68%	-49.10%

Apr. 12	Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 27	Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

The company benefits from high valuations in earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
NOVOGENE CO., LTD.	-49.10%	677M	-
SONIC HEALTHCARE LIMITED	-22.13%	7.9B	B+
RADNET, INC.	+76.22%	4.53B	C+
DR. LAL PATHLABS LIMITED	+8.00%	2.78B	B-
SYNLAB AG	-2.80%	2.64B	-
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-50.41%	1.99B	B-
NEOGENOMICS, INC.	-20.40%	1.66B	C-
FLEURY S.A.	-20.12%	1.49B	A-
METROPOLIS HEALTHCARE LIMITED	+19.31%	1.23B	B+
DIAN DIAGNOSTICS GROUP CO.,LTD.	-45.78%	1.1B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality